InMode Ltd. $INMD Shares Bought by CWA Asset Management Group LLC

CWA Asset Management Group LLC lifted its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 62.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 92,070 shares of the healthcare company’s stock after acquiring an additional 35,465 shares during the period. CWA Asset Management Group LLC’s holdings in InMode were worth $1,372,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP acquired a new stake in shares of InMode during the 2nd quarter worth $1,397,000. Focus Partners Wealth increased its stake in InMode by 31.8% during the first quarter. Focus Partners Wealth now owns 227,959 shares of the healthcare company’s stock worth $4,044,000 after acquiring an additional 54,948 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of InMode by 6.6% in the 1st quarter. Acadian Asset Management LLC now owns 556,413 shares of the healthcare company’s stock worth $9,858,000 after purchasing an additional 34,623 shares during the period. OMERS ADMINISTRATION Corp lifted its stake in shares of InMode by 55.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 200,043 shares of the healthcare company’s stock valued at $2,889,000 after purchasing an additional 71,231 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of InMode by 92.9% in the 2nd quarter. Squarepoint Ops LLC now owns 143,758 shares of the healthcare company’s stock valued at $2,076,000 after purchasing an additional 69,239 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of InMode from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Friday, October 10th. Canaccord Genuity Group set a $15.00 price target on InMode and gave the company a “hold” rating in a report on Wednesday, December 17th. Finally, Zacks Research raised InMode from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. One investment analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, InMode has a consensus rating of “Hold” and a consensus target price of $16.60.

InMode Price Performance

Shares of INMD stock opened at $15.55 on Wednesday. The firm has a market cap of $982.92 million, a P/E ratio of 7.20 and a beta of 2.13. InMode Ltd. has a 1-year low of $13.14 and a 1-year high of $19.78. The firm has a fifty day moving average of $14.44 and a two-hundred day moving average of $14.65.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.